The Detroit Tigers have reached agreement with veteran reliever Emilio Pagán on a one-year deal that could pay up to $12.5 million with incentives, pending a physical examination required to finalize the contract. The deal, worth a reported $11.5 million in base salary with up to $1 million in games-finished bonuses, was confirmed on November 17, marking a significant development as Detroit pivots from its previous bullpen strategy.

Pagán, age 35, arrives from the Cincinnati Reds—where he posted a 5-1 record and a 3.38 earned run average across the 2026 season, converting 25 of 28 save opportunities. Despite missing nearly two months with a strained hamstring, Pagán’s performance, particularly in high-leverage situations, has prompted the Tigers to invest heavily in his closing experience. He declined a $10 million player option to remain with Cincinnati for 2027, opting instead to test free agency.

The news comes as Detroit continues to overhaul its bullpen. In the days leading up to Pagán’s signing, the Tigers declined a $12 million option on closer Kenley Jansen, electing for a $2 million buyout after just one season with the club. The move underpins a strategic shift: rather than retaining the aging Jansen, Detroit is seeking relievers capable of generating more strikeouts and flexibility late in games.

Pagán’s contract includes incentive payments contingent on games finished—$200,000 for each of the 35, 40, 45, 50, and 55 games-finished marks—underscoring the organization’s expectation that he’ll anchor the late innings in 2027. Over a decade-long career, Pagán has notched 90 saves while pitching for six major-league teams including the Mariners, Rays, Athletics, Padres, Twins, and Reds.

While industry sources differ slightly on the base value of the agreement—with some reporting $11 million and others $11.5 million—consensus remains that the contract’s finalization depends on Pagán successfully completing the standard physical examination mandated for all MLB free agent signings. The Tigers’ bullpen, active with offseason transactions, appears poised to feature Pagán in a leading role if all proceeds as expected.

For Detroit, this move represents a targeted response to bullpen struggles in recent seasons. Should Pagán clear his medical assessment, the Tigers will officially secure a closer with a proven track record and the potential for high-leverage reliability heading into the 2027 campaign.